Anita T. Shaffer


Frontline Treatment of Metastatic NSCLC Depends on Biomarkers and Histology

November 21, 2018

Choosing frontline therapy for patients with metastatic non–small cell lung cancer (NSCLC) who do not harbor an actionable driver oncogene depends upon PD-L1 expression level and histology, according to Gregory J. Riely, MD, PhD.

Regorafenib Sustains OS Benefit in RESORCE Trial Update

September 26, 2018

Regorafenib (Stivarga) maintained a prolonged overall survival (OS) benefit as second-line therapy for patients with advanced hepatocellular carcinoma (HCC) in a 2-year updated analysis of key findings from the pivotal RESORCE trial.

Four-Drug Chemo Combo Significantly Improves Pancreatic Cancer Survival

July 09, 2018

In a major advance that set a new standard of care for the treatment of patients with resected pancreatic cancer, a modified FOLFIRINOX regimen (mFOLFIRINOX) dramatically improved survival compared with standard gemcitabine as postoperative therapy.

Lung Cancer Survival Improved in Patients Who Used a Web App to Report Symptoms

June 07, 2016

Researchers in France have found that patients with lung cancer who used a web-based app to report and track their symptoms achieved impressive gains in survival compared with individuals who were followed using standard protocols.

Daratumumab Combo Safe and Effective in Multiple Myeloma

December 08, 2015

The CD38 monoclonal antibody daratumumab in combination with lenalidomide and dexamethasone proved to be safe and showed an 81% response rate in patients with relapsed or refractory multiple myeloma, according to research presented at the 2015 ASH Annual Meeting.